Professional Perspective

Patenting Compounds, Compositions, and Methods for Viral Infections

Gaby L. Longsworth and Robert Greene Sterne, Sterne Kessler

Reproduced with permission. Published March 2020. Copyright © 2020 The Bureau of National Affairs, Inc. 800.372.1033. For further use, please visit: http://bna.com/copyright-permission-request/
Patenting Compounds, Compositions, and Methods for Viral Infections

Contributed by Gaby L. Longsworth and Robert Greene Sterne, Sterne Kessler

The new coronavirus, the cause of coronavirus disease Covid-19, is the third major global outbreak of a coronavirus in the past 20 years. The spread of Covid-19 brings into sharp focus the issues surrounding patenting antiviral research and preserving exclusive marketing rights for companies developing products, diagnostic assays and kits, and treatments for viral infections.

While continued research for new antivirals is extremely important for global human health, on a practical level, successfully patenting an invention to protect the inventor’s intellectual property and related exclusive marketing rights are critical for companies wishing to invest in and profit from treatments for viral infections. Understanding viral mechanisms of action is essential for designing novel antiviral agents and obtaining the necessary intellectual property protection. This article explains the types of treatments used for fighting viral infections like Covid-19 and examines their patentability under U.S. law.

Treatments for Viral Infections

Viruses are intracellular pathogens that, at times throughout history, have been the source of plagues affecting human health. Viruses have developed many Machiavellian strategies to evade host immune responses and, as a result, combating viral diseases with vaccines and antiviral drugs is a constant challenge. Even when successful strategies are devised and implemented, the high rate of genetic change exhibited by many viruses renders those treatments ineffective.

Compared to bacteria, viruses have different mechanisms and machinery to survive and replicate in a host. Bacteria can reproduce on their own, whereas viruses must insert their genetic material into a host’s cells to reproduce. The virus then hijacks the host cell’s machinery to reproduce and fill the cell with viral particles. When the cell ruptures, the virus spreads to other cells and repeats the process.

Antibiotics used to treat bacterial infections are ineffective against viruses as there is no target to attack in a virus. Unlike most antibiotics, antiviral drugs typically do not destroy their target pathogen but instead inhibit their development and/or reproduction. To prevent a person from developing a viral infection in the first place, vaccines are used. Thus, vaccines are a preemptive first line of defense. Antiviral drugs and vaccines will be discussed in turn below.

Small Molecule Antivirals

Small molecule inhibitors typically arise out of a structure-based design of the viral target. There are many steps in a virus life cycle that can be targeted by potential antiviral drug candidates. This approach involves a detailed knowledge of viral action and lifecycle leading to different strategies for curing or treating viral disease, such as:

- Preventing viral adhesion to host cells (inhibitors of host-cell receptors)
- Inhibiting hemagglutinin induced membrane fusion
- Inhibiting viral escape from endosome (protease inhibitors)
- Preventing the release of viral particles (blocking neuraminidase)
- Blocking ion-channels
- Blocking RNA packaging
- Accelerating capsid assembly
- Preventing viral reproduction (blocking integrase or reverse transcriptase)
- Enhancing intracellular innate immunity
• Targeting viral DNA-packaging motors
• Inhibiting viral RNA processing (targeting viral polymerase complex)
• Disrupting viral assembly (nucleoprotein)

Novel compounds and methods of use are fairly easy to patent. Crystal forms, hydrates, and solvates are generally also readily patented.

Some examples of the many Food and Drug Administration-approved protease inhibitors include: atazanavir (Reyataz), darunavir (Prezista), fosamprenavir (Lexiva), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Invirase).

Other types of viral inhibitors are baloxavir marboxil (Xofluza), zanamivir (Relenza), and oseltamivir (Tamiflu), which prevent the release of viral particles by blocking neuraminidase on the surface of flu viruses, and doravirine (Pifeltro), a new reverse transcriptase inhibitor.

Table 1 lists some small molecule antiviral drugs and their relevant patent claims. These are examples of compound claims routinely obtained when filing a patent application on a novel small molecule antiviral drug. Follow-on patent applications that claim solvates, crystal forms, and methods of treatment of novel drugs are also valuable because they are typically difficult to design around or invalidate.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Viral Target</th>
<th>Patent and Representative Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prezista (darunavir)</td>
<td>HIV protease</td>
<td>U.S. Patent No. 8,518,987; Title: Pseudopolymorphic forms of a HIV protease inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. An ethanolate solvate of the compound (3R,3αS,6αR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-<a href="isobutyl">(4-aminophenyl)sulfonyl</a>amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1.</td>
</tr>
<tr>
<td>Vosevi (voxilaprevir)</td>
<td>Hepatitis C, inhibits viral replication</td>
<td>U.S. Patent No. 8,735,372; Title: Nucleoside phosphoramidate prodrugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. A method of treating a human infected by hepatitis C virus, comprising administering to the subject an effective amount of an NS5a inhibitor and an effective amount of a compound represented by the following formula [ ].</td>
</tr>
<tr>
<td>Xofluza (baloxavir marboxil)</td>
<td>Influenza A and B endonuclease</td>
<td>U.S. Patent No. 8,927,710; Title: Substituted polycyclic carbamoylpyridone derivative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. A CAP dependent endonuclease inhibitor compound represented by formula (I), a pharmaceutically acceptable salt, or a solvate thereof [ ].</td>
</tr>
<tr>
<td>Sitavig (acyclovir)</td>
<td>Herpes labialis DNA polymerase</td>
<td>U.S. Patent No. 8,592,434; Title: Mucoadhesive buccal tablets for the treatment of orofacial herpes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. A method for treating orofacial herpes comprising administering to a patient suffering from orofacial herpes only a single dose of a prolonged release mucoadhesive buccal tablet comprising: 50 to 200 mg of acyclovir, 1 to 75% by weight of a diluent, 1 to 10% by weight of an alkali metal alkylsulfate, to 5% by weight of a binding agent, 5 to 80% by weight of natural milk proteins, and 5% to 80% by weight of at least one hydrophilic polymer that provides a sustained release of acyclovir.</td>
</tr>
</tbody>
</table>
Table 1: Exemplary Small Molecule Antiviral Drugs and Relevant Patent Claims

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Viral Target</th>
<th>Patent and Representative Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOXX (tecovirimat)</td>
<td>Smallpox (variola virus), blocks viral particle release</td>
<td>U.S. Patent No. 8,802,714; Title: Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. A method of treating or preventing an infection caused by an orthopox virus in a living host having or susceptible to said infection, said method comprising administering to said living host a therapeutically effective amount of a mixture of compounds comprising: (a) N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[1]isoindol-2(1H)-yl]-4-(trifluoromethyl)benzamide; and (b) N-[(3aR,4S,4aS,5aR,6R,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[1]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide, or a pharmaceutically acceptable salt thereof.</td>
</tr>
</tbody>
</table>

Vaccines

While most antiviral small molecule drugs treat acute or chronic viral infections, vaccines are a preemptive first line of defense. Vaccines stimulate the immune system to produce antibodies that remain in the body for long periods of time. Because of such long-term “immune memory,” a rapid immune response typically results upon subsequent exposure to the virus. In this way, a virus can be eradicated before it causes harm.

Developing a vaccine typically takes years and involves a lengthy process of testing on animals, clinical trials on humans, and regulatory approvals. Vaccines are more difficult and expensive to manufacture and test in human clinical trials than small molecule antiviral drugs. Despite the cost and decades of research and development necessary to design a vaccine, this research is absolutely vital for creating new viral treatments to guarantee continued global human health.

Vaccine IP is complex and characterized by multiple levels of patents, including patents directed to DNA and amino acid sequences, viral vectors, attenuated strains, formulations, culturing and manufacturing methods, methods of use, and kits and devices for vaccine administration. The various types of vaccine-related patents are generally readily obtained, assuming the requirements for patentability are met.

Table 2 lists some exemplary patent claims in the vaccine space. Claims directed to stable vaccines, multivalent immunogenic compositions, live attenuated viral strains, methods of making virus-like particles, methods of vaccinating a patient or inducing an immune response, and vectors are routinely obtained when filing a patent application on a new vaccine target.

Table 2: Exemplary Patent Claims in the Vaccine Space

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Viral Target</th>
<th>Exemplary Patent Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFANRIX</td>
<td>Diphtheria and tetanus toxoids and acellular pertussis</td>
<td>U.S. Patent No. 9,233,151; Title: Vaccine composition</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. A multivalent immunogenic composition comprising the following components: (a) killed whole-cell Bordetella pertussis, (b) tetanus toxoid, (c) diphtheria toxoid, (d) Hepatitis B surface antigen, (e) a conjugate of a carrier protein and the capsular polysaccharide of Haemophilus influenzae type B and (f) one or more conjugates of a carrier protein and the capsular polysaccharide of a bacterium selected from the group consisting of Neisseria meningitidis type A and N. meningitidis type C.</td>
</tr>
<tr>
<td>Brand Name</td>
<td>Viral Target</td>
<td>Exemplary Patent Claim</td>
</tr>
<tr>
<td>------------</td>
<td>--------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| BIOTHRX   | Bacillus anthrax | U.S. Patent No. 8,778,359; Title: Stable anthrax vaccine formulations  
1. A stable vaccine for stimulating an immune response to a Bacillus anthracis protective antigen comprising:  
a) a purified B. anthracis protective antigen protein;  
b) an alanine formulation buffer; and  
c) a pharmaceutically acceptable adjuvant. |
| DENGVAXIA | Dengue disease | U.S. Patent No. 9,169,298; Title: Dengue serotype 1 attenuated strain  
1. A live attenuated dengue-1 virus strain which comprises an RNA sequence having the sequence of SEQ ID NO: 3 wherein said RNA sequence comprises uridines in place of the deoxythymidines in SEQ ID NO: 3, wherein at least nucleotides at positions 5962 and 7947 of the RNA sequence are mutated with reference to SEQ ID NO: 3, with the proviso that the following nucleotides of the RNA sequence are not mutated: 1323, 1541, 1543, 1545, 1567, 1608, 2363, 2695, 2782, 5063, 6048, 6806, 7330, and 9445. |
| GARDASIL 9 | Human papillomavirus | U.S. Patent No. 7,476,389; Title: Papillomavirus vaccines  
1. A method of making a papillomavirus virus-like particle, which method comprises:  
constructing a recombinant DNA molecule that contains a sequence encoding a papillomavirus L1 protein;  
transfecting a host cell with the recombinant DNA molecule;  
expressing papillomavirus L1 protein in the host cell; and  
obtaining papillomavirus virus-like particles from the transfected host cell; wherein the papillomavirus is not HPV 16. |
| PROQUAD | Measles, mumps, rubella, and varicella virus | U.S. Patent No. 10,350,289; Title: Methods of immunization with varicella zoster virus antigen  
1. A method of vaccinating a patient against varicella zoster virus (VZV) infection or reactivation of latent VZV infection comprising injecting an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the patient’s skin at a depth of between 100 and 700 microns from the surface of the skin, wherein the live attenuated VZV vaccine is liquid and comprises a live attenuated VZV strain, and wherein the VZV vaccine is injected with an intradermal delivery device comprising one or more hollow needles for penetrating the skin, wherein the device is adapted for shallow intradermal delivery of the VZV vaccine. |
| IMOVAX | Rabies | U.S. Patent No. 9,750,800; Title: Method for purifying the rabies virus  
1. A vaccine comprising purified and inactivated rabies virus, wherein the amount of residual DNA measured by quantitative PCR and the amount of total protein present in one effective dose of vaccine or in one dose of vaccine which contains 2.5 IU as measured according to the European Pharmacopeia monograph number 0216, are, respectively, less than 20 pg and less than 40 μg. |
# Table 2: Exemplary Patent Claims in the Vaccine Space

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Viral Target</th>
<th>Exemplary Patent Claim</th>
</tr>
</thead>
</table>
| JYNNEOS    | Smallpox and monkey pox    | U.S. Patent No. 9,707,291; Title: Single high dose of MVA induces a protective immune response in neonates and infants  
1. A method for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age comprising administering a dose of at least 108 50% tissue culture infectious dose (TCID50) of a modified vaccinia virus Ankara (MVA) to a human neonate, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate prior to 6 months of age in the absence of a second administration of the MVA. |
| RECOMBIVAX HB | Hepatitis B               | U.S. Patent No. 6,544,757; Title: Synthesis of human virus antigens by yeast  
1. A DNA transfer vector comprising a yeast replication origin, a yeast promoter fragment and, in correct orientation with said promoter fragment, a DNA segment coding for the S-protein of Hepatitis B virus. |
| n/a        | SARS                      | U.S. Patent No. 10130701; Title: Coronavirus  
1. A live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or both of non-structural protein(s) nsp-10 and nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6, and/or wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7.  
15. |
| n/a        | H5N1 avian influenza      | U.S. Patent No. 9,283,198 ; Title: Materials and methods for treating viral infections  
1. A method for treating a subject infected with H5N1 strain of avian influenza, wherein said method comprises diagnosing a subject as being infected with the H5N1 strain of avian influenza; and administering to the subject an effective amount of a salt of cysteamine. |

## Subject Matter Eligibility Considerations

Patent attorneys and their clients looking to enter the antiviral or vaccine space must consider whether the invention at issue is likely to be eligible for patent protection.

### Small Molecules

Novel compounds are patent eligible because they do not exist in nature. Other forms of these compounds, such as crystal forms, hydrates, and solvates, as well as methods of treatment, are also eligible and patents are generally easily obtained. A new use for an old compound is typically patentable assuming the use is novel and nonobvious. For example, numerous antivirals, such as HIV drugs, have entered clinical trials to test whether they can be used safely and effectively against the current coronavirus, and patent applications have been filed for the new use.

### Vaccines

Claims directed to a newly discovered, wild-type strain of a virus are not patentable in the U.S. This is because a product of nature, i.e., a wild-type virus strain not modified by humans, is not eligible for patent protection. However, a genetically modified viral strain that differs structurally from the wild-type virus is patentable.
Claims directed to a vaccine composition comprising a live attenuated virus are generally considered patentable subject matter because a live attenuated virus has different structural and functional characteristics than what occurs in nature. Because the live attenuated virus has markedly different characteristics from what exists in nature, and is not a “product of nature,” it qualifies as patent-eligible subject matter. Virus-like particles and viruses obtained by recombinant DNA technology are also patentable.

Claims directed to a vaccine composition comprising an antigenic peptide and a pharmaceutically acceptable carrier, such as water, are not patent eligible because each component is a product of nature. While the mixture of these two naturally occurring components is novel, there is no indication that mixing these components changes the structure, function, or other properties of the peptide or water in any marked way. Instead, the peptide retains its naturally occurring structure and function, and is merely dispersed in the water, which also retains its naturally occurring structure and function. Thus, the claim as a whole would not amount to significantly more than each “product of nature” by itself and does not qualify as eligible subject matter because their combination is well-understood, routine, and conventional in the field.

In contrast, claims directed to a vaccine composition comprising an antigenic peptide and a pharmaceutically-acceptable carrier selected from the group consisting of a cream, emulsion, gel, liposome, nanoparticle, or ointment, would be patent eligible because the plain meaning of each carrier recited in the claim requires that the carrier have structural and physical characteristics that distinguish it from the closest counterpart in nature.

Along the same lines, claims directed to a vaccine composition comprising an antigenic peptide and a specific adjuvant would be patent eligible because the mixture has a changed functional property, in that the immunogenicity of the mixture is different (higher) than the mere “sum” of the immunogenicity of the individual components.

The patentability of in vitro diagnostic methods, i.e., using a biological sample isolated from a patient, is in flux in the U.S. Medical diagnostics claims continue to be struck down by U.S. courts on the ground of subject matter ineligibility. However, the application of diagnostic results, even in conventional and routine ways, may be patentable. In other words, method of treatment claims that practically apply natural relationships are considered patent eligible under 35 U.S.C. §101.

**Antivirals and IP**

Innovation and new drug approvals are sorely needed to prevent viral outbreaks or treat viral infections. It is concerning that fewer companies are investing in the development of vaccines. To incentivize innovation and research and development, the role of global agreements should be explored, similarly to the so-called Pandemic Influenza Preparedness Framework, which rewards countries for sharing viruses with human pandemic potential in order to further research that will aid preparedness and response. Additional agreements similar to the PIP can be created for global viral outbreaks, such as the Covid-19 coronavirus. However, without gaining exclusive IP protection and marketing rights for a significant period of time, profit-minded companies will have little incentive to invest in the research and development necessary to develop diagnostics, vaccines, and antiviral medications.